PGNX
Progenics Pharmaceuticals, Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.
Market Cap: 355 Million
Primary Exchange: NASDAQ
Website: http://www.progenics.com
Shares Outstanding: 86.6 Million
Float: 78.3 Million
Dividend: (%)
Beta: 1.694782913004788
Sector: Health Technology
Industry: Biotechnology
Ethical Flags
Longest drawdown: 904 trading days
From: 2017-03-15 To: 2020-06-19
Lowest Point:
Mid-stage study underway for Progenics' I-131 1095 in prostate cancer
via: SeekingAlpha at 2019-06-13 04:50:33:000
The first patient has been dosed in a Phase 2 clinical trial, ARROW , evaluating Progenics Pharmaceuticals' (NASDAQ: PGNX ) I-131 1095 radiotherapy, combined with Pfizer (NYSE: PFE ) and Astellas' ( OTCPK:ALPMY ) XTANDI (enzalutamide), for the treatment of metastatic castration-res… read more...
Key events next week - healthcare
via: SeekingAlpha at 2019-06-13 03:28:10:000
Noteworthy events during the week of June 16 - 22 for healthcare investors. More news on: ProMIS Neurosciences, Inc., Merck & Co., Inc., IQVIA Holdings Inc., Healthcare stocks news, , Read more … read more...
CytoDyn: Uncovering An Opportunity
via: SeekingAlpha at 2019-06-12 05:05:12:000
I discovered CytoDyn (CYDY) when performing research for an article on Progenics Pharmaceuticals (PGNX). As I was reading through PGNX SEC filings, I saw a few references to Leronlimab (PRO 140) , a fully humanized monoclonal antibody treatment for HIV that CytoDyn acquired from Progenics b… read more...
Velan Capital Sends Letter to Stockholders Calling Out Progenics Pharmaceuticals' Board for Unnecessarily Diluting Stockholders to Support Outsized And Undeserved Compensation
via: PR Newswire at 2019-06-11 04:30:00:000
ALPHARETTA, Ga. , June 11, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics")(NASDAQ: PGNX), announced today that it has delivered a letter t… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|